227 related articles for article (PubMed ID: 27305776)
41. Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9.
Zheng Y; Qin Z; Ye Q; Chen P; Wang Z; Yan Q; Luo Z; Liu X; Zhou Y; Xiong W; Ma J; Li G
Lab Invest; 2014 Nov; 94(11):1188-99. PubMed ID: 25068657
[TBL] [Abstract][Full Text] [Related]
42. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.
Tzartos JS; Khan G; Vossenkamper A; Cruz-Sadaba M; Lonardi S; Sefia E; Meager A; Elia A; Middeldorp JM; Clemens M; Farrell PJ; Giovannoni G; Meier UC
Neurology; 2012 Jan; 78(1):15-23. PubMed ID: 22156987
[TBL] [Abstract][Full Text] [Related]
43. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
44. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection.
Sugaya N; Kimura H; Hara S; Hoshino Y; Kojima S; Morishima T; Tsurumi T; Kuzushima K
J Infect Dis; 2004 Sep; 190(5):985-8. PubMed ID: 15295706
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
46. EBV latent membrane protein 1 is a negative regulator of TLR9.
Fathallah I; Parroche P; Gruffat H; Zannetti C; Johansson H; Yue J; Manet E; Tommasino M; Sylla BS; Hasan UA
J Immunol; 2010 Dec; 185(11):6439-47. PubMed ID: 20980631
[TBL] [Abstract][Full Text] [Related]
47. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
48. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
Dasari V; Bhatt KH; Smith C; Khanna R
Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck.
Auerbach A; Aguilera NS
Semin Diagn Pathol; 2015 Jan; 32(1):12-22. PubMed ID: 25804341
[TBL] [Abstract][Full Text] [Related]
50. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape.
Severa M; Giacomini E; Gafa V; Anastasiadou E; Rizzo F; Corazzari M; Romagnoli A; Trivedi P; Fimia GM; Coccia EM
Eur J Immunol; 2013 Jan; 43(1):147-58. PubMed ID: 22996354
[TBL] [Abstract][Full Text] [Related]
51. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
52. Early virological and immunological events in Epstein-Barr virus infection.
Hislop AD
Curr Opin Virol; 2015 Dec; 15():75-9. PubMed ID: 26322696
[TBL] [Abstract][Full Text] [Related]
53. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
54. Manipulation of immune responses by Epstein-Barr virus.
Levitsky V; Masucci MG
Virus Res; 2002 Sep; 88(1-2):71-86. PubMed ID: 12297328
[TBL] [Abstract][Full Text] [Related]
55. Host genetics of Epstein-Barr virus infection, latency and disease.
Houldcroft CJ; Kellam P
Rev Med Virol; 2015 Mar; 25(2):71-84. PubMed ID: 25430668
[TBL] [Abstract][Full Text] [Related]
56. Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma.
Farina A; Rosato E; York M; Gewurz BE; Trojanowska M; Farina GA
Front Immunol; 2021; 12():651013. PubMed ID: 33953718
[TBL] [Abstract][Full Text] [Related]
57. Mice with Reconstituted Human Immune System Components as a Tool to Study Immune Cell Interactions in EBV Infection.
Heuts F; Nagy N
Methods Mol Biol; 2017; 1532():229-240. PubMed ID: 27873280
[TBL] [Abstract][Full Text] [Related]
58. MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity.
Albanese M; Tagawa T; Buschle A; Hammerschmidt W
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592533
[TBL] [Abstract][Full Text] [Related]
59. Animal models of Epstein Barr virus infection.
Chatterjee B; Leung CS; Münz C
J Immunol Methods; 2014 Aug; 410():80-7. PubMed ID: 24815603
[TBL] [Abstract][Full Text] [Related]
60. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.
Martorelli D; Muraro E; Merlo A; Turrini R; Faè DA; Rosato A; Dolcetti R
Clin Dev Immunol; 2012; 2012():931952. PubMed ID: 22319542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
